MedImmune and Dutch firm Crucell NV have signed a license deal to develop and commercialize certain proteins to treat hospital-acquired bacterial infections. Crucell will receive more than $40 million and possible milestone payments, and MedImmune will gain access to the firm's antibody technology for broader research and development studies.
The latest research on diabetes shows that the disease could be caused by a hormone from the skeleton and that signals from the immune system could play a critical role. Research that probes organs, cells and molecules in search of a clue to the body's sugar control indicate a major shift in the paradigm of diabetes research, one diabetes expert said.
StemLifeLine's proposal to store stem cells from embryos produced through in vitro fertilization exploits parents' worries about their children's future, a British stem cell expert said. Other experts agreed, saying that it's "too early" to store the stem cells because the science doesn't yet prove they could be useful. The California-based biotech firm says the process could be used to help develop new treatments in the future.
Covidien Ltd. and BioSynthema said they have a signed a licensing deal to develop a radionuclide drug for the treatment of neuroendocrine cancer. Under the deal, Covidien will get marketing rights to the cancer treatment technology, and BioSynthema will gain access to Covidien's technology.
Scientists are developing biotech poplar trees that are better at wiping out hazardous contaminants, airborne pollutants and RDX, a toxic explosive, than regular plants. Researchers intend to conduct a further study to guarantee that biotech plants do not impact nontarget organisms.